A new preclinical 3-dimensional agarose colony formation assay

Technology in Cancer Research and Treatment

Volumn 7, Issue 4, 2008, Pages 329-334

  Kajiwara, Yoshinori ^a   Panchabhai, Sonali ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carboplatin; DFMO; GelCount ; HDAC inhibitor; ODC

Indexed keywords

CARBOPLATIN; EFLORNITHINE; VORINOSTAT;

AGAR MEDIUM; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; GLIOMA CELL; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; PANCREAS ADENOCARCINOMA; THREE DIMENSIONAL IMAGING;

EID: 50249101225     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460800700407     Document Type: Article

References (21)

1. Thompson, H., Meeker, L., Herbst, E., Ronan, A., Minocha, R. Effect of concentration of D,L-2-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res 45, 1170-1173 (1985).
2. Thompson, H. J., Ronan, A. M., Ritacco, K. A.Meeker, L. D. Effect of tamoxifen and D,L-2-difluoromethylornithine on the growth, ornithine decarboxylase activity and polyamine content of mammary carcinomas induced by 1-methyl-1-nitrosourea. Carcinogenesis 7, 837-840 (1986).
3. Persson, L. Rosengren, E. Increased formation of N1-acetylspermidine in human breast cancer. Cancer Lett 45, 83-86 (1989).
4. Gerner, E. W., Mamont, P. S., Bernhardt, A., Siat, M. Post-translational modification of the protein-synthesis initiation factor eIF-4D by spermidine in rat hepatoma cells. Biochem J 239, 379-386 (1986).
5. Manni, A., Washington, S., Craig, L., Cloud, M., Griffith, J. W., Verderame, M. F., Texter, L. J., Mauger, D., Demers, L. M., Harms, J. F., Welch, D. R. Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. Clin Exp Metastasis 20, 321-325 (2003).
6. Manni, A., Washington, S., Griffith, J. W., Verderame, M. F., Mauger, D., Demers, L. M., Samant, R. S., Welch, D. R. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19, 95-105 (2002).
7. Oredsson, S. M., Deen, D. F., Marton, L. J. Decreased cytotoxicity of cis-diamminedichloroplatinum(II) by alpha-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cells in vitro. Cancer Res 42, 1296-1299 (1982).
8. Tofilon, P. J., Oredsson, S. M., Deen, D. F., Marton, L. J. Polyamine depletion influences drug-induced chromosomal damage. Science 217, 1044-1046 (1982).
9. Tofilon, P. J., Deen, D. F., Marton, L. J. alpha-Difluoromethylornithine- induced polyamine depletion of 9L tumor cells modifies drug-induced DNA cross-link formation. Science 222, 1132-1135 (1983).
10. Chang, B. K., Gutman, R., Chou, T. C. Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. Cancer Research 47, 2247-2250 (1987).
11. Milam, K. M., Deen, D. F., Marton, L. J. Cell proliferation and polyamine metabolism in 9L cells treated with (2r,5r)-6-heptyne-2,5-diamine or alpha-difluoromethylornithine. Cell & Tissue Kinetics 22, 269-277 (1989).
12. Chang, B. K., Black, O., Gutman, R. Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II). Cancer Research 44, 5100-5104 (1984).
13. Allen, E. D., Natale, R. B. Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro. Cancer Res 46, 3550-3555, (1986).
14. Kurihara, H., Matsuzaki, S., Tamura, M., Sugimoto, H., Tsukahara, T., Yamazaki, H. alpha-Difluoromethylornithine increases the antitumor effect of cis-diamminedichloroplatinum in G-XII rat glioma. Neurologia Medico-Chirurgica 35, 215-220, (1995).
15. Bhalla, K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23, 3971-3993 (2005).
16. Dokmanovic, M., Marks, P. A. Prospects: histone deacetylase inhibitors. J Cell Biochem 96, 293-304 (2005).
17. Johnstone, R. W., Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18 (2003).
18. Minucci, S., Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51 (2006).
19. Yoo, C. B., Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50 (2006).
20. Van Schaeybroeck, S., Karaiskou-McCaul, A., Kelly, D., Longley, D., Galligan, L., Van Cutsem, E., Johnston, P. Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy. Clin Cancer Res 11, 7480-7489 (2005).
21. Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., Melillo, G., Elsayed, Y., Monga, M., Kalnitskiy, M., Zwiebel, J., Sausville, E. A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23, 3912-3922, (2005).